ClinicalTrials.gg
TerminatedNCT05060978Updated May 16, 2023

Evaluation of the Effect of Two Online Interventions -Watch Your Weight During the Holidays Program and the Relative 5:2 Fasting- for the Prevention of Body Weight Gain at 8 Weeks in Mexican Adults in the Covid-19 Pandemic

An interventional study of Watch your Weight During the Holidays Program and Relative 5:2 Fasting in Weight Gain, Overweight and Obesity, sponsored by Universidad de Sonora. Terminated at 1 site in Mexico. Open to participants aged 20 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-05-16.

Sponsored by Universidad de Sonora · Not applicable, Interventional, and Prevention

Why this study was terminated
Due to the retention of 78.1% of the participants obtained for the first measurement (after the December holidays), we believe that waiting one more year to complete the study would not be feasible for a subsequent definitive study.
Phase
Not applicable
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
20 Years to 60 Years
Sex
All
01

Study summary

Introduction. Obesity is the main risk factor for the development of chronic degenerative diseases in Mexico and other countries around the world. Due to the difficulty of treating obesity, it is necessary to change the curative paradigm for a preventive one. A review showed that holiday periods during the year are critical points for weight gain. The holiday season is the festive period with the greatest impact on adults' body weight. Observational studies have shown that more than 50% of the annual weight is gained during this period. However, few preventive interventions in the festive period have been carried out globally. Additionally, the COVID-19 pandemic seems to be negatively affecting diet, physical activity and body weight. So preventive interventions are needed, especially those that can be implemented in an online format. The purpose of the study is to evaluate the effect of two online interventions -Watch your Weight during the Holidays Program and the Relative 5:2 Fasting - on the prevention of body weight gain from baseline to 8 weeks in comparison with a control group in Mexican adults during the COVID-19 pandemic. Methodology: This is a Pilot Randomized Controlled Trial (RCT). The primary outcome is the change in body weight from baseline to 8 weeks. Secondary outcomes are the percentage of retention / desertion of the participants, adherence to interventions, participant satisfaction scale, changes in other obesity parameters, biochemical, physical, and quality of life variables from baseline to 8 weeks. Obesity and quality of life parameters from baseline to 52 weeks are also secondary outcomes. The statistical analysis of the primary and secondary variables will be conducted, according to their distribution, by intention to treat and, secondarily, by completer´s analysis.

02

Conditions studied

  • Weight Gain
  • Overweight
  • Obesity

Keywords

  • Holiday Season
  • Normal weight
  • Prevention
03

In context

Weight Gain

317 studies on the registry are indexed under Weight Gain; 48 are open to participants now.

This study's enrollment of 32 is below the median of 83 across 251 interventional studies indexed under Weight Gain.

Browse Weight Gain studies →

Lead sponsor

Universidad de Sonora is the lead sponsor of 15 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Mexican adult participants (≥20 and ≤60 years)
  • Residents of the city of Hermosillo, Sonora
  • ≥ 23 kg/m2 and ≤ 40 kg/m2
  • Availability and motivation to attend the intervention program
  • Committed to not undertake any other intervention in place of, or in combination with, the one assigned in the study during the 8 weeks of the intervention

Exclusion criteria

Exclusion Criteria:

  • Diagnosed medical conditions that constitute a for intervention such as: diabetes, hypertension, diseases with an effect on body weight (for example: liver failure; cancer in treatment or in advanced stage; history of COVID-19 that required hospitalization, supplemental oxygen or has left sequelae that contraindicates the intervention; psychiatric conditions; eating disorders, etc.).
  • Use of drugs or substances with an effect on weight, for example, metformin, orlistat, , etc.
  • Use of addictive substances such as drugs of abuse
  • Previous bariatric surgery.
  • Being a participant in another intervention or treatment for the management of obesity.
  • Weight loss > 5% of total body weight in the last 4 months.
  • Having plans to become pregnant within the study period, currently pregnant or breastfeeding.
  • Another family member has agreed to participate in the study.
  • Illiteracy.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
32 participants (actual)

Study arms

  • Active comparator
    Watch your Weight During the Holidays Program

    Behavioral: Watch your Weight During the Holidays Program

  • Active comparator
    Relative 5:2 Fasting

    Other: Relative 5:2 Fasting

  • Placebo comparator
    Control Group

    Other: Control Group

Interventions

  • BehavioralWatch your Weight During the Holidays Program

    Participants in this group will have two video call individual sessions and one video call group session. This intervention will include self-monitoring strategies (self-weighing, diet monitoring and physical activity), and nutrition counseling and education. In addition, participants in this group will receive a weighing scale to achieve self-monitoring of body weight from the beginning of the study intervention until the end of the 52-weeks follow-up.

  • OtherRelative 5:2 Fasting

    Participants in this group will will have two video call individual sessions and one video call group session. This intervention will receive eating recommendations to follow a 5:2 intermittent fasting. They will be given low-calorie menus of 550 kcal and 660 kcal, for women and men respectively, which the participants in this group will apply on fasting days. The fasting will be held twice a week and on the remaining five days, the participants will not have any type of caloric restriction (it will be ad libitum). They will only have the general recommendation to adhere to a healthy dietary pattern.

  • OtherControl Group

    Participants in this group will receive online information and a PDF file brochure during an individual video call session at the beginning of the 8-week period. This information will be about leading a healthy eating based on the norm for health promotion and education for healthy eating in Mexico (NOM-043-SSA2-2012).

06

What researchers measure

Primary outcomes

  1. Changes in body weight

    Time frame: Baseline to 8 weeks

Secondary outcomes

  1. Changes in body weight

    Time frame: Baseline and 52 weeks

  2. Changes in kilograms of body fat

    Time frame: Baseline, 8 weeks and 52 weeks

  3. Changes in waist circumference

    Time frame: Baseline, 8 weeks and 52 weeks

  4. Changes in systolic blood pressure

    Time frame: Baseline, 8 weeks and 52 weeks

  5. Changes in diastolic blood pressure

    Time frame: Baseline, 8 weeks and 52 weeks

  6. Changes in perception of health related quality of life

    The SF-36 Health Survey evaluates aspects of the quality of life in adult populations (over 16 years of age). The result of its application is the generation of eight concepts or scales of health, result of the average of the sum of the questions contained in the questionnaire for each concept. These concepts are: physical function, physical role, corporal pain, general health, vitality, social function, emotional role and mental health. The SF-36 is a self-applied instrument and contains 36 questions. For each scale, the answers to each question are coded and recoded (10 questions), and the results are interpreted on a scale of 0 to 100, lower results indicate poorer health and greater result better health.

    Time frame: Baseline, 8 weeks and 52 weeks

  7. Retention / desertion

    The retention percentage will be obtained by dividing the number of people that finished the intervention the number that started the intervention, multiplied by 100. The dropout percentage will be obtained by the difference in the number of subjects who started and finished the intervention, multiplied by 100.

    Time frame: 8 weeks and 52 weeks

  8. Adherence to intervention

    Adherence to the intervention will be calculated as the percentage of study measurement appointments and group sessions attended by each participant. Another way to measure adherence to interventions will be with a numerical scale of self-evaluation from 1 to 5, where 1 is the lowest score and 5 is the highest, to indicate how adherent they were to the meal plans.

    Time frame: 8 weeks and 52 weeks

  9. Participant satisfaction scale

    Satisfaction of the participants in each of the intervention groups will be measured online using a scale from 1 to 5, where 1 is the lowest rating and 5 is the highest. A higher score means a higher satisfaction with the intervention recieved.

    Time frame: 8 weeks and 52 weeks

  10. Changes in fasting glucose

    Time frame: Baseline and 8 weeks

  11. Changes in total cholesterol

    Time frame: Baseline and 8 weeks

  12. Changes in LDL cholesterol

    Time frame: Baseline and 8 weeks

  13. Changes in HDL cholesterol

    Time frame: Baseline and 8 weeks

  14. Changes in triglycerides

    Time frame: Baseline and 8 weeks

07

Study locations

1 site
  • Centro de Promoción de Salud Nutricional (CPSN)
    Hermosillo, Sonora 83000, Mexico
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2021 to primary completion in Feb 2022, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2021
First posted
Sep 29, 2021
StartActual
Nov 10, 2021
Primary completionActual
Feb 11, 2022
CompletionActual
Feb 11, 2022
Last update
May 16, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 16, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05060978
Lead sponsor
Universidad de Sonora
Responsible party
Rolando Giovanni Díaz Zavala (Research Professor, Universidad de Sonora) — Principal investigator
First posted
Sep 29, 2021
Start date
Nov 10, 2021
Primary completion
Feb 11, 2022
Completion
Feb 11, 2022
Last update
May 16, 2023

Study contacts

Rolando G Díaz Zavala, Ph.D.
principal investigator · Universidad de Sonora

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion